MX2020006307A - Compuesto ciclico de 6 miembros que contiene nitrogeno. - Google Patents

Compuesto ciclico de 6 miembros que contiene nitrogeno.

Info

Publication number
MX2020006307A
MX2020006307A MX2020006307A MX2020006307A MX2020006307A MX 2020006307 A MX2020006307 A MX 2020006307A MX 2020006307 A MX2020006307 A MX 2020006307A MX 2020006307 A MX2020006307 A MX 2020006307A MX 2020006307 A MX2020006307 A MX 2020006307A
Authority
MX
Mexico
Prior art keywords
nitrogen
membered ring
ring compound
promotion
salt
Prior art date
Application number
MX2020006307A
Other languages
English (en)
Inventor
Daisuke Shikanai
Noriko Ishiguro
Osamu Omori
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of MX2020006307A publication Critical patent/MX2020006307A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un nuevo compuesto representado por la siguiente fórmula general (1), o una sal del mismo, que tiene una actividad agonista del receptor EP4 superior, y un medicamento que contiene el compuesto o una sal del mismo como ingrediente activo, que puede usarse para promover la osteogénesis, tratamiento terapéutico y/o promoción de curación de fracturas y similares.
MX2020006307A 2017-12-25 2018-12-25 Compuesto ciclico de 6 miembros que contiene nitrogeno. MX2020006307A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017248173 2017-12-25
PCT/JP2018/047450 WO2019131582A1 (ja) 2017-12-25 2018-12-25 含窒素６員環化合物

Publications (1)

Publication Number Publication Date
MX2020006307A true MX2020006307A (es) 2020-09-17

Family

ID=67063663

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006307A MX2020006307A (es) 2017-12-25 2018-12-25 Compuesto ciclico de 6 miembros que contiene nitrogeno.

Country Status (12)

Country Link
US (2) US10988468B2 (es)
EP (1) EP3733665B1 (es)
JP (1) JP6896106B2 (es)
KR (1) KR102446027B1 (es)
CN (1) CN111511736B (es)
AU (1) AU2018396402C1 (es)
CA (1) CA3086662C (es)
ES (1) ES2929799T3 (es)
MX (1) MX2020006307A (es)
PL (1) PL3733665T3 (es)
PT (1) PT3733665T (es)
WO (1) WO2019131582A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006307A (es) * 2017-12-25 2020-09-17 Asahi Kasei Pharma Corp Compuesto ciclico de 6 miembros que contiene nitrogeno.
WO2020227592A1 (en) 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Thiosemicarbazates and uses thereof
US11883461B2 (en) 2019-05-09 2024-01-30 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of severe sepsis
EP3965792A4 (en) 2019-05-09 2023-01-18 The Feinstein Institutes for Medical Research HMGB1 ANTAGONIST
CN111440141A (zh) * 2020-05-20 2020-07-24 安徽泽升科技有限公司 一种羟甲基取代芳杂环类化合物的制备方法
CN111718353B (zh) * 2020-08-04 2023-02-10 许昌恒生制药有限公司 一种磷酸西格列汀的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
MXPA03004623A (es) * 2000-11-27 2003-09-05 Pfizer Prod Inc Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
CA2451393C (en) 2001-07-16 2011-01-04 F. Hoffmann-La Roche Ag 2 pyrrolidone derivatives as prostanoid agonists
WO2003009872A1 (en) 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
DE60226051T2 (de) 2001-10-23 2009-05-20 Laboratoires Serono S.A., Coinsins Pyrazolidinon-verbindungen als liganden des ep2 und/oder ep4 prostaglandin-rezeptoren
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
JP2006515015A (ja) 2003-01-10 2006-05-18 エフ．ホフマン−ラ　ロシュ　アーゲー プロスタグランジンアゴニストとしての２−ピペリドン誘導体
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
EP1707208A4 (en) 2003-12-05 2010-03-17 Ono Pharmaceutical Co PROMOTER OF BLOOD FLOW IN THE TISSUES OF THE HORSE TAIL
JP4888775B2 (ja) 2004-08-10 2012-02-29 小野薬品工業株式会社 Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
CN101133037B (zh) * 2005-01-27 2012-05-09 旭化成制药株式会社 六元杂环化合物及其用途
BRPI0611079A2 (pt) 2005-06-03 2010-08-03 Ono Pharmaceutical Co agentes para a regeneração e/ou proteção de nervos
EP1912957A4 (en) * 2005-08-03 2009-05-13 Merck Frosst Canada Ltd EP4 AGONIST RECEIVER, COMPOSITIONS AND METHODS RESULTING THEREFROM
EP1912977A4 (en) * 2005-08-03 2009-10-21 Merck Frosst Canada Ltd EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
EP3235817B1 (en) 2013-03-15 2018-12-12 Cayman Chemical Company, Incorporated Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
MX2020006307A (es) * 2017-12-25 2020-09-17 Asahi Kasei Pharma Corp Compuesto ciclico de 6 miembros que contiene nitrogeno.

Also Published As

Publication number Publication date
KR20200073265A (ko) 2020-06-23
RU2020120817A (ru) 2022-01-27
JPWO2019131582A1 (ja) 2021-01-14
AU2018396402A1 (en) 2020-07-09
EP3733665B1 (en) 2022-09-28
AU2018396402B2 (en) 2020-10-29
US10988468B2 (en) 2021-04-27
ES2929799T3 (es) 2022-12-01
US11667630B2 (en) 2023-06-06
CA3086662C (en) 2022-01-25
JP6896106B2 (ja) 2021-06-30
CN111511736A (zh) 2020-08-07
PT3733665T (pt) 2022-10-21
US20200347046A1 (en) 2020-11-05
BR112020012405A2 (pt) 2020-11-24
EP3733665A1 (en) 2020-11-04
EP3733665A4 (en) 2021-06-02
CA3086662A1 (en) 2019-07-04
WO2019131582A1 (ja) 2019-07-04
AU2018396402C1 (en) 2021-03-18
KR102446027B1 (ko) 2022-09-21
CN111511736B (zh) 2023-03-24
RU2020120817A3 (es) 2022-01-27
PL3733665T3 (pl) 2023-02-06
US20210188837A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
MX2020006307A (es) Compuesto ciclico de 6 miembros que contiene nitrogeno.
PH12020551821A1 (en) Novel compounds
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
GEP20237506B (en) Pcsk9 antagonist compounds
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
GEP20227443B (en) Magl inhibitors
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2019010085A (es) Inhibidores de la glicosidasa de sulfoximina.
MY176401A (en) Novel disubstituted 1,2,4-triazine compound
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
PH12020550133A1 (en) Crystal forms of immunomodulators
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
TN2016000491A1 (en) Carboxamide derivatives.
EA201692300A1 (ru) Производные карбоксамида
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
AU2017370226A1 (en) Pharmaceutical composition containing insulin-like growth factor-2 and use thereof
BR112021018084A8 (pt) Medicamento e método para tratamento ou prevenção de complicações de diabetes usando o mesmo medicamento
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
PH12019502261A1 (en) Therapeutic or prophylactic agent for peripheral neuropathies
EA202190316A1 (ru) Конденсированное производное лактама